Applied Therapeutics Says FDA Extends Review Period Of NDA For Govorestat
29/3 07:24
(RTTNews) - Applied Therapeutics, Inc. (APLT) said on Friday that the U.S. Food and Drug Administration or FDA has extended the review period of the New Drug Application or NDA for Govorestat, AT-007, to treat Classic Galactosemia by three months to November 28....